a provider of health insurance services
Industry ManagedHealthCare
This is a signal that CI's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options. A.I.dvisor looked back and found 36 similar cases where CI's RSI Indicator left the overbought zone, and in of them led to a successful outcome. Odds of Success:
CI saw its Momentum Indicator move below the 0 level on November 17, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 93 similar instances where the indicator turned negative. In 55 of the 93 cases, the stock moved further down in the following days. The odds of a decline are at 59%.
The Moving Average Convergence Divergence Histogram (MACD) for CI turned negative on October 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 29 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 58%.
CI moved below its 50-day moving average on November 18, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The 50-day moving average for CI moved above the 200-day moving average on October 16, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +1.31% 3-day Advance, the price is estimated to grow further. Considering data from situations where CI advanced for three days, in 226 of 357 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
CI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 175 of 274 cases where CI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 64%.
The Tickeron PE Growth Rating for this company is 47 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.820) is normal, around the industry mean (3.520). P/E Ratio (12.077) is within average values for comparable stocks, (126.353). Projected Growth (PEG Ratio) (0.739) is also within normal values, averaging (0.786). CI has a moderately high Dividend Yield (0.021) as compared to the industry average of (0.009). P/S Ratio (0.264) is also within normal values, averaging (0.569).
The Tickeron Profit vs. Risk Rating rating for this company is 54 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock slightly better than average.
The Tickeron SMR rating for this company is 55 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating fairly steady price growth. CI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
Cigna Group shares closed near $298.23 on October 30, 2026, after a volatile stretch that saw the stock climb to a 52-week intraday high of $316.27 on October 22 before giving back roughly 5% over the following sessions. The pullback coincided with profit-taking after a sharp multi-week run and renewed political and regulatory attention on health insurers and pharmacy benefit managers. Despite the retreat, the stock remains higher by approximately 9.7% over the trailing 30 days, a move that underscores renewed investor interest in a name that had lagged the broader market for much of the year.
The Cigna Group is a global health company headquartered in Bloomfield, Connecticut, operating through two primary divisions. Evernorth Health Services — which includes pharmacy benefit management (Express Scripts), specialty pharmacy, and care services — generates the largest share of revenue, while Cigna Healthcare provides medical plans and coordinated health solutions across commercial and international markets. The company maintains customer relationships in more than 30 markets and jurisdictions. Key growth drivers include specialty pharmacy expansion, biosimilar adoption, and a transition toward a transparent, rebate-free pharmacy model, while medical cost management and customer retention remain important competitive considerations.
Several verified developments shaped Cigna's stock over the trailing 30 days. The company's September 30 Investor Day introduced its "Lead to One" vision, a $3 billion multi-year modernization and productivity initiative, and a long-term target of 10%–14% adjusted EPS compound annual growth through 2030. On October 6, Cigna Healthcare launched Health Sense, a personalized support model aimed at improving affordability and outcomes, initially focused on oncology and cardiometabolic conditions. The company also declared a quarterly dividend of $1.56 per share on October 28. On the analyst front, ratings were mixed, with firms such as Bernstein and RBC maintaining Buy/Outperform views while others, including Leerink and Evercore ISI, held at Hold. The pullback from the October 22 high coincided with a House investigation involving major pharmacy benefit managers and renewed scrutiny of insurers over Affordable Care Act coverage, contributing to sector-wide caution. Second-quarter results, reported in late July, showed revenue up 7% to $71.7 billion and adjusted EPS of $7.78, prompting management to raise its full-year 2026 adjusted EPS outlook to at least $30.45.
Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots. While Tickeron offers hundreds of bots that trade thousands of tickers, only the top-performing and most relevant strategies appear in this section, giving traders a streamlined view of what is currently working. The bots vary widely in strategy, timeframe, and performance metrics, allowing users to compare approaches across momentum, swing, and other algorithmic styles. It is a useful starting point for investors interested in systematic, data-driven trading ideas.
Looking ahead, investors are likely to monitor Cigna's November 5 third-quarter earnings release for confirmation of its adjusted EPS trajectory and any updates to the 2026 outlook, given analyst expectations for a year-over-year earnings decline on a reported basis. Key themes include the progress of the $3 billion modernization program, adoption of the rebate-free Signature pharmacy model, and specialty pharmacy growth, which has been a principal earnings driver. Medical cost trends — Cigna's medical care ratio rose to 84.5% in the second quarter from 83.2% a year earlier — and ongoing regulatory scrutiny of pharmacy benefit managers and health insurers represent the most visible risks. Valuation remains compressed relative to historical levels, but execution on cost management, customer retention, and productivity savings will be central to the stock's direction through the rest of 2026 and into 2027.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.